Serotonin 5-HT 2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism
ACS Chemical Neuroscience · 01.10.2025 · 16 (19) · 3899-3914
DOI: 10.1021/acschemneuro.5c00647 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 13.09.2025. Verfasst von Emma M Bonniwell und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States. Hauptthemen laut MEDLINE: Receptor, Serotonin, 5-HT2C, Hallucinogens, Signal Transduction, Serotonin 5-HT2 Receptor Agonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIDCD NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
The serotonin 2C receptor (5-HT2C) is a G protein-coupled receptor implicated in multiple physiological and psychological processes and has been investigated as a therapeutic target for neuropsychiatric conditions such as obesity, drug abuse, and depression. With renewed interest in serotonergic psychedelics for treating depression, 5-HT2C may contribute to psychedelic-induced therapeutic effects. Despite earlier evidence of 5-HT2C G protein coupling promiscuity, the full signaling landscape remains incompletely characterized, which may help explain the limited efficacy and potential cancer risks associated with lorcaserin. Here, we provide a comprehensive analysis of 5-HT2C signaling, confirming and building upon previous findings that the receptor engages Gi/o/z and G12/13 proteins in addition to its primary Gq/11 pathway, and that it preferentially recruits β-arrestin2 over β-arrestin1. We also show that increased RNA editing of the receptor attenuates signaling across all G protein pathways, particularly for G12/13, while preserving β-arrestin recruitment. Profiling of both 5-HT2C-selective and psychedelic ligands reveals diverse signaling profiles, with serotonergic psychedelics such as LSD and psilocin exhibiting a striking Gq/11 bias due to minimal secondary G protein activation. Altogether, this work provides a foundation for incorporating a broader view of 5-HT2C signaling modalities into future investigations of 5-HT2C drug development efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
- Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York 14642, United States.
- Department of Pharmacology and Toxicology, Neuroscience Research Center, Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
ORCID-Profile: Emma M Bonniwell, Joseph J Hennessey, John L McKee, Natalie G Cavalco, Josie C Lammers, Cesare Orlandi, John D McCorvy
Förderung
- NIDA NIH HHS
- NIDCD NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Bonniwell, E. M., Alabdali, R., Hennessey, J. J., McKee, J. L., Cavalco, N. G., Lammers, J. C., Moore, E. J., Franchini, L., Orlandi, C., & McCorvy, J. D. (2025). Serotonin 5-HT 2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism. ACS Chemical Neuroscience, 16(19), 3899-3914. https://doi.org/10.1021/acschemneuro.5c00647
Vancouver
Bonniwell EM, Alabdali R, Hennessey JJ, McKee JL, Cavalco NG, Lammers JC, et al. Serotonin 5-HT 2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism. ACS Chemical Neuroscience. 2025;16(19):3899-3914. doi:10.1021/acschemneuro.5c00647
BibTeX
@article{Bonniwell2025,
author = {Bonniwell, Emma M and Alabdali, Rana and Hennessey, Joseph J and McKee, John L and Cavalco, Natalie G and Lammers, Josie C and Moore, Ethan J and Franchini, Luca and Orlandi, Cesare and McCorvy, John D},
title = {Serotonin 5-HT 2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism},
journal = {ACS Chemical Neuroscience},
year = {2025},
volume = {16},
number = {19},
pages = {3899--3914},
doi = {10.1021/acschemneuro.5c00647}
}
EUVIMED